We scale healthtech internationally.
Making US commercialization strategy clear for EU companies, opening mutual collaboration across the Atlantic, and investing in long-term successes.
We teach, connect scaleups with strategic partners, bridge policy and innovation, and work on the investment side too. We also co-run an accelerator for international startups to get guaranteed US hospital pilots.
The US deciphered for the EU and ANZ
From the health economics and sales strategies that matter to how to defend value propositions and clinical proof from abroad, we have virtual and in-person workshops tailored for international entrepreneurs with busy schedules.
Informed investment and policy
We work with governments and policymakers around the world to better inform decisions that impact innovators and patients. Innovators can join our Current Affairs series and systems can inquire to join the Life Science Diplomacy Alliance.
US hospital pilots, surface area, strategy
The HealthTech Bridge is an accelerator specifically designed for international startups to enter the US with what they need: information that’s actually relevant, strategy, and guaranteed hospital pilots. Rural health technologies is now opening for applicants.
Go far, go fast, and go with the right people
Strategy
We provide education and 1:1 strategic work to help scaleups lower their commercial risk as they enter the US.
Scale
SCALE matches highly relevant scaleups with US strategic partners in clinical workflow for mutual benefits.
Capital
The Venture Atlas Labs Capital Network reviews, conducts due diligence, and syndicates early-stage deals monthly.
Supporting European and ANZ scaleups where it’s the most needed—so they can play to their strengths
Leveling the playing field for
resilience and impact
Most focus on getting you in the game: regulatory, reimbursement, legal setup, payroll.
It’s important, but it’s table stakes. To win, you need a viable strategy, commercial partners, and funding that works for you.
We address the critical areas that cost international scaleups the most—very different business models, a very long sales cycle with high commercial risk, and difficulty raising sufficient operating capital.
Instead, we’re focused on helping you succeed commercially—and by defining your strategy first, you can refine areas like regulatory pathways accurately the first time.
The US healthcare market is a spectrum of different models, some of which may highlight your unique value better than others—and some of which may be completely incompatible with your business.
We don’t want to cover up the perspectives and insights that made you successful abroad. We want to leverage them to your competitive advantage and to the advantage of our health systems, clinicians, and patients.
